Literature DB >> 20870050

Cortical and trabecular bone at the radius and tibia in postmenopausal breast cancer patients: a Peripheral Quantitative Computed Tomography (pQCT) study.

K A Szabo1, C E Webber, J D Adachi, R Tozer, C Gordon, A Papaioannou.   

Abstract

Bone morbidity associated with antineoplastic treatment is a significant health concern for postmenopausal breast cancer patients. Trials have demonstrated that adjuvant therapy with an Aromatase Inhibitor is associated with an increase in musculoskeletal disorders and bone fractures. The objective of this study was to utilize Peripheral Quantitative Computed Tomography (pQCT) to assess in vivo trabecular and cortical volumetric bone at peripheral skeletal sites in healthy postmenopausal women and breast cancer patients prescribed Anastrozole. Fifty-eight women were recruited for this study: 27 breast cancer patients and 31 healthy control participants. pQCT measurements were taken at distal and diaphyseal sites of the radius and tibia using a Stratec XCT-2000 pQCT scanner. Bone measurement values for total density and total content at the 4% radius; total and cortical content as well as cortical density at the 20% radius; total density at the 4% tibia; and cortical density at the 38% tibia were found to be significantly lower in breast cancer patients. Moreover, the duration of time on Anastrozole showed a significant negative correlation with the following measurements: total content at the 4% radius (r=-0.36, p<0.01); total content (r=-0.33, p<0.05), cortical content (r=-0.34, p<0.05) and cortical density (r=-0.44, p<0.01) at the 20% radius; as well as cortical density (r=-0.39, p<0.01) and cortical content (r=-0.27, p<0.05) at the 38% tibia. Overall, the breast cancer patients demonstrated significantly lower values for volumetric bone density and content at the radius and tibia compared with healthy postmenopausal women. Furthermore, this novel study found adverse effects from Anastrozole treatment primarily in cortical bone. Copyright Â
© 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20870050      PMCID: PMC5104538          DOI: 10.1016/j.bone.2010.09.025

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  20 in total

1.  Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.

Authors:  Alan S Coates; Aparna Keshaviah; Beat Thürlimann; Henning Mouridsen; Louis Mauriac; John F Forbes; Robert Paridaens; Monica Castiglione-Gertsch; Richard D Gelber; Marco Colleoni; István Láng; Lucia Del Mastro; Ian Smith; Jacquie Chirgwin; Jean-Marie Nogaret; Tadeusz Pienkowski; Andrew Wardley; Erik H Jakobsen; Karen N Price; Aron Goldhirsch
Journal:  J Clin Oncol       Date:  2007-01-02       Impact factor: 44.544

2.  Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.

Authors:  Raimund Jakesz; Walter Jonat; Michael Gnant; Martina Mittlboeck; Richard Greil; Christoph Tausch; Joern Hilfrich; Werner Kwasny; Christian Menzel; Hellmut Samonigg; Michael Seifert; Guenther Gademann; Manfred Kaufmann; Johann Wolfgang
Journal:  Lancet       Date:  2005 Aug 6-12       Impact factor: 79.321

3.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

Authors:  A Howell; J Cuzick; M Baum; A Buzdar; M Dowsett; J F Forbes; G Hoctin-Boes; J Houghton; G Y Locker; J S Tobias
Journal:  Lancet       Date:  2005 Jan 1-7       Impact factor: 79.321

4.  A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

Authors:  Beat Thürlimann; Aparna Keshaviah; Alan S Coates; Henning Mouridsen; Louis Mauriac; John F Forbes; Robert Paridaens; Monica Castiglione-Gertsch; Richard D Gelber; Manuela Rabaglio; Ian Smith; Andrew Wardley; Andrew Wardly; Karen N Price; Aron Goldhirsch
Journal:  N Engl J Med       Date:  2005-12-29       Impact factor: 91.245

5.  Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).

Authors:  Richard Eastell; Rosemary A Hannon; Jack Cuzick; Mitch Dowsett; Glen Clack; Judith E Adams
Journal:  J Bone Miner Res       Date:  2006-08       Impact factor: 6.741

6.  Fracture of the distal forearm as a forecaster of subsequent hip fracture: a population-based cohort study with 24 years of follow-up.

Authors:  H Mallmin; S Ljunghall; I Persson; T Naessén; U B Krusemo; R Bergström
Journal:  Calcif Tissue Int       Date:  1993-04       Impact factor: 4.333

7.  Mechanical validation of a tomographic (pQCT) index for noninvasive estimation of rat femur bending strength.

Authors:  J L Ferretti; R F Capozza; J R Zanchetta
Journal:  Bone       Date:  1996-02       Impact factor: 4.398

8.  Colles' fracture of the wrist as an indicator of underlying osteoporosis in postmenopausal women: a prospective study of bone mineral density and bone turnover rate.

Authors:  S A Earnshaw; S A Cawte; A Worley; D J Hosking
Journal:  Osteoporos Int       Date:  1998       Impact factor: 4.507

9.  Long-term fracture prediction by bone mineral assessed at different skeletal sites.

Authors:  L J Melton; E J Atkinson; W M O'Fallon; H W Wahner; B L Riggs
Journal:  J Bone Miner Res       Date:  1993-10       Impact factor: 6.741

10.  Predicting various fragility fractures in women by forearm bone densitometry: a follow-up study.

Authors:  P Gärdsell; O Johnell; B E Nilsson; B Gullberg
Journal:  Calcif Tissue Int       Date:  1993-05       Impact factor: 4.333

View more
  6 in total

1.  Cortical and trabecular bone at the radius and tibia in male and female adolescents with Down syndrome: a peripheral quantitative computed tomography (pQCT) study.

Authors:  A González-Agüero; G Vicente-Rodríguez; A Gómez-Cabello; J A Casajús
Journal:  Osteoporos Int       Date:  2012-06-09       Impact factor: 4.507

2.  Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.

Authors:  R Rizzoli; J J Body; A DeCensi; A De Censi; J Y Reginster; P Piscitelli; M L Brandi
Journal:  Osteoporos Int       Date:  2012-01-20       Impact factor: 4.507

3.  Effect of whole body vibration training on bone mineral density and bone quality in adolescents with Down syndrome: a randomized controlled trial.

Authors:  A Matute-Llorente; A González-Agüero; A Gómez-Cabello; H Olmedillas; G Vicente-Rodríguez; J A Casajús
Journal:  Osteoporos Int       Date:  2015-05-21       Impact factor: 4.507

4.  Associations of muscle force, power, cross-sectional muscle area and bone geometry in older UK men.

Authors:  Ayse Zengin; Stephen R Pye; Michael J Cook; Judith E Adams; Rainer Rawer; Frederick C W Wu; Terence W O'Neill; Kate A Ward
Journal:  J Cachexia Sarcopenia Muscle       Date:  2017-05-04       Impact factor: 12.910

5.  Reliability of upper-limb diaphyseal mineral and soft-tissue measurements using peripheral Quantitative Computed Tomography (pQCT).

Authors:  Mark A Jenkins; Nicolas H Hart; Timo Rantalainen; Paola Chivers; Robert U Newton; Sophia Nimphius
Journal:  J Musculoskelet Neuronal Interact       Date:  2018-12-01       Impact factor: 2.041

6.  The prevalence of sarcopenia and relationships between muscle and bone in ageing West-African Gambian men and women.

Authors:  Ayse Zengin; Landing M Jarjou; Ann Prentice; Cyrus Cooper; Peter R Ebeling; Kate A Ward
Journal:  J Cachexia Sarcopenia Muscle       Date:  2018-09-16       Impact factor: 12.910

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.